Two years into the global COVID-19 pandemic, private equity interest in healthcare and life sciences remains at an all-time high. The National Law Review takes a look at the fields that look to offer the most promising opportunities in 2022.
The healthcare sector has seen enormous enthusiasm and infusion of funds during the pandemic, and the pace of transactions shows no signs of slowing anytime soon.
Several factors have contributed to this highly active market. A brief transaction slowdown in early 2020 resulted in a backlog of available deals and extra dry powder. Simultaneously, COVID-19 spurred demand for digital health solutions and opened doors for new technology to improve care delivery, access, and outcomes across the board. The pandemic also dramatically underscored the value of health data, clinical research and biopharma development. Read more.
